Introduction
There is much to report from the realm of liver tumors. The incidence of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma, is increasing worldwide. Although direct acting antivirals and vaccination protocols provide hope of decreasing the burden of chronic hepatitis C and B respectively as leading causes of HCC, the global epidemic of fatty liver disease and metabolic syndrome appears to provide a novel and rather fertile milieu for the development of HCC. Many HCCs arising in a background of non-alcoholic fatty liver disease occur in the absence of cirrhosis and these tumors may recapitulate the features of steatohepatitis.
Source: Seminars in Diagnostic Pathology - Category: Pathology Authors: Romil Saxena Source Type: research
More News: Alcoholism | Bile Duct Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Cirrhosis | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Hepatitis | Hepatitis C | Hepatitis Vaccine | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pathology | Urology & Nephrology | Vaccines